Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics — Stella

Home/Influenza/First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

View on ClinicalTrials.gov

Recruiting

Back to Influenza trials

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Altasciences Inc - Kansas City, Overland Park, Kansas

Key details

Phase

Early testing

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment target

~78 participants

Started

September 2025

Primary completion

April 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 59 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.